Update in Pediatric Psychiatry

Chapter

Abstract

More than 50% of psychiatric illnesses that cause morbidity and mortality in adulthood have their onset in childhood and adolescence. Moreover greater than 20% of children and youth have a diagnosable psychiatric illness at any time with the majority meeting criteria for more than one. Furthermore, many children and youth have identifiable subsyndromal symptoms of illness that cause distress and impairment, warranting attention and heralding the potential for worsening to full blown manifestation of disorder. Recognizing that most psychiatric illnesses are neurodevelopmental in nature and fit within a clinical staging framework is essential. In this framework symptom severity exists on a fluid continuum from normal variant to full manifestation of illness. Understanding where the youth’s presentation fits within this process is essential to fostering accurate and reliable identification of illness manifestation. This new concept underscores the exciting potential for clinicians working in the field of child and adolescent psychiatry for early identification, intervention and possible prevention of morbidity associated with psychiatric illnesses. The new organisation of the DSMV reflects this approach to illness development aiding the curious clinician in making appropriate diagnostic decisions. Outlined are some of the clinical updates regarding psychiatric disorders that present in childhood and adolescence that are in keeping with the new framework. Information presented should be used in conjunction with the DSMV (or other accepted psychiatric diagnostic guide) to enable clinicians to make decisions that foster optimum care for their young patients.

Keywords

Childhood Adolescent Psychiatric illness Early intervention Pharmacotherapy Clinical update Mental health Clinical care Pediatric psychiatry ADHD Anxiety Depression Psychosis Addictions 

References

  1. American Academy of Child and Adolescent Psychiatry. Practice parameters for the use of atypical Antipsychotic medications in children and adolescents. 2011. https://www.aacap.org/App_Themes/AACAP/docs/practice_parameteres/atypical_antipsychotic_medicaitons_web.pdf.
  2. American Academy of Pediatrics, Committee on substances abuse and committee on adolescence. Technical report: the impact of marijuana policies on youth: clinical, research and legal update. Pediatrics. 2015;135(3).Google Scholar
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5 edn (DSM-V). Washington, DC: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  4. Andover MS, Morris BW, Wren A, Bruzzese ME. The co-occurrence of non-suicidal self-injury and attempted suicide among adolescents: distinguishing risk factors and psychosocial correlates. Child Adolesc Psychiatr Ment Health. 2012;6:11.CrossRefGoogle Scholar
  5. Angold A, Costello EJ. Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues. Am J Psychiatry. 1993;150:1779–91.CrossRefGoogle Scholar
  6. Avenevoli S, Swendson J, He J, et al. Major depression in the national comorbidity survey–adolescent supplement: prevalence, correlates, and treatment. J Am Acad Child Adolesc Psychiatry. 2015;54:37–44.e2.CrossRefGoogle Scholar
  7. Beesdo K, Pine DS, Lieb R, Wittchen H-U. Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder. Arch Gen Psychiatry. 2010;67(1):47–57.CrossRefGoogle Scholar
  8. Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric properties of the screen for child anxiety related emotional disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry. 1999;38(10):1230–6.CrossRefGoogle Scholar
  9. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized control trial. JAMA. 2008;299:901–13.CrossRefGoogle Scholar
  10. Bridge JA, Yengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;63:332–9.Google Scholar
  11. Bussing R, Mason DM, Bell L, et al. Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample. J Am Acad Child Adolesc Psychiatry. 2010;49:595–605.PubMedPubMedCentralGoogle Scholar
  12. Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic outcomes in children and adolescents following discontinuation of long term risperidone treatment. J Child Adoelsc Psychopharmacol. 2014;24:120–9.CrossRefGoogle Scholar
  13. Centred for Disease Control and Prevention. Youth risk behavior surveillance – United States. MMWR. 2012;61:11–2.Google Scholar
  14. Chang KD. Diagnosing bipolar disorder in children and adolescents. J Clin Psychiatry. 2009;70(11):e41.  https://doi.org/10.4088/JCP.8125tx7c.CrossRefPubMedGoogle Scholar
  15. Chang LY, Wang MY, Tsai PS. Diagnostic accuracy of rating scales for attention-deficit/hyperactivity disorder: a meta-analysis. Pediatrics. 2016;137(3):1–15.CrossRefGoogle Scholar
  16. Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.CrossRefGoogle Scholar
  17. Collins GA, McAllister MS, Adury K. (2016) Drug abuse and addiction. Cleveland Clinic Centre for Continuing Education Lyndhurst, OH. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/psychiatry-psychology/drug-abuse-and-addiction/. Accessed 25 June 2016.
  18. Committee on Substance Abuse, Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):584–7.  https://doi.org/10.1542/peds.2014-4146.CrossRefGoogle Scholar
  19. Correll CU, Kratochvil CJ, Marcj JS. Developments in pediatrics psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry. 2011;72:655–70.CrossRefGoogle Scholar
  20. Cosgrove VE, Roybal D, Chang KD. Bipolar depression in pediatric populations: epidemiology and management. Pediatr Drugs. 2013;15(2):83–91.CrossRefGoogle Scholar
  21. Dilillo D, Mauri S, Mantegazza C, Fabiano V, Mameli C, Zucotti GV. Suicide in pediatrics: epidemiology, risk factors, warning signs and the role of the pediatrician detecting them. Ital J Pediatr. 2015;41:49.  https://doi.org/10.1186/s13052-015-0153-3.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Dunn V, Goodyer IA. Longitudinal investigation into childhood- and adolescence- onset depression: psychiatric outcome in early adulthood. Br J Psychiatry. 2006;188:216–22.CrossRefGoogle Scholar
  23. Faraone SV. Using meta-analysis to compare the efficacy of medication for attention-deficit/hyperactivity disorder in youth. P T. 2009;34:678–94.PubMedPubMedCentralGoogle Scholar
  24. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15–21.PubMedGoogle Scholar
  25. Giles LL, Martini R. Challenges and promises of pediatric psychopharmacology. Acad Pediatr. 2016;16:508–18.CrossRefGoogle Scholar
  26. Gillberg C. Epidemiology of early onset schizophrenia. In: Remschmidt H, editor. Schizophrenia in children and adolescents. Cambridge: Cambridge University Press; 2001. p. 43–59.Google Scholar
  27. Girolamo G, Dagani J, Purcell R, Cocchi A, McGorry PD. Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiol Psychiatr Sci. 2012;21:47–57.CrossRefGoogle Scholar
  28. Gore FM, Bloem PJN, Patton GC, Ferguson J, Joseph V, Coffey C, Sawyer SM, Mathers CD. Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet. 2011;377(9783):2093–102.CrossRefGoogle Scholar
  29. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health. Psychopharmacology Research Branch; 1976. 1976:534–537 NIMH. DHEW Pub. No (ADM)Google Scholar
  30. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;3:CD004851.Google Scholar
  31. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53:153–73.CrossRefGoogle Scholar
  32. Jackson KM, Sher KJ, Wood PK. Trajectories of concurrent substance use disorders: a developmental, typological approach to comorbidity. Alcohol Clin Exp Res. 2000;24:902–13.CrossRefGoogle Scholar
  33. Jensen CM, Steinhausen H-C. Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7:27–38.CrossRefGoogle Scholar
  34. Kendall PC, Compton SN, Walkup JT, et al. Clinical characteristics of anxiety disordered youth. J Anxiety Disord. 2010;24(3):36–5.CrossRefGoogle Scholar
  35. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.CrossRefGoogle Scholar
  36. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.CrossRefGoogle Scholar
  37. Klein DN, Shankman SA, Lewinsohn PM, et al. Subthreshold depressive disorder in adolescents: predictors of escalation to full-syndrome depressive disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:703–10.CrossRefGoogle Scholar
  38. Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156:607–14.CrossRefGoogle Scholar
  39. Lachman A. New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents. J Child Adolesc Mental Health. 2014;26(2):109–24.CrossRefGoogle Scholar
  40. Leibenluft E. Severe mood dysregulation, irritability and the diagnostic boundaries of bipolar disorder in youth. Am J Psychiatry. 2011;168(2):129–42.CrossRefGoogle Scholar
  41. MacDonald K, Pappas K. Why not pot? A review of the brain-based risks of cannabis. Innov Clin Neurosci. 2016;13(3-4):13–22.PubMedPubMedCentralGoogle Scholar
  42. March JS, Vitiello B. Clinical messages from the treatment for adolescents with depression study (TADS). Am J Psychiatry. 2009;166:1118–23.CrossRefGoogle Scholar
  43. March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(4):554–65.CrossRefGoogle Scholar
  44. March J, Silva S, Petrycki S, et al. Treatment for adolescents with depression study (TADS) team. fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA. 2004;292:807–20.CrossRefGoogle Scholar
  45. McGorry PD, Purcell R, Hickie IB, Jorm AF. Investing in youth mental health is a best buy. Med J Aust. 2007a;187(Suppl. 7):S5.Google Scholar
  46. McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust. 2007b;187(Suppl. 7):S40–2.PubMedGoogle Scholar
  47. McGuiness TM, Durand SC. Update on anxiety disorder in childhood and adolescence. J Psychosoc Nurs Ment Health Serv. 2016;54(6):25–8.CrossRefGoogle Scholar
  48. Muehlenkamp JJ, Claes L, Havertape L, Plener PL. International prevalence of adolescent non-suicidal self-injury and deliberate self-harm. Child Adolesc Psychiatr Ment Health. 2012;6:10.CrossRefGoogle Scholar
  49. National Collaborating Centre for Mental Health (UK). Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care. Leicester: British Psychological Society; 2005. (NICE Clinical Guidelines, No. 28.)Google Scholar
  50. Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United states. JAMA Psychiat. 2015;72:867–74.CrossRefGoogle Scholar
  51. Pediatric OCD Treatment Study (POTS) Team. Cognitive behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the pediatric OCD treatment study (POTS) randomized controlled trial. JAMA. 2004;292:1969–76.CrossRefGoogle Scholar
  52. Pisano S, Catone G, Veltri S, et al. Update on the safety of second generation antipsychotics in youths: a call for collaboration among pediatricians and child psychiatrists. Ital J Pediatr. 2016;42:51.  https://doi.org/10.1186/s13052-016-0259-2.CrossRefPubMedPubMedCentralGoogle Scholar
  53. Polanczyk GV, Salum G, Sugaya LS, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–65.CrossRefGoogle Scholar
  54. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2001;3:1–2.Google Scholar
  55. Prinsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second generation Antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34:651–68.CrossRefGoogle Scholar
  56. Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot – a review of the association between cannabis and psychosis. Front Psych. 2014;5:54.Google Scholar
  57. Rynn MA, Walkup JT, Compton SN. Child/adolescent anxiety multimodal study: evaluating safety. J Am Acad Child Adolesc Psychiatry. 2015;54(3):180–90.CrossRefGoogle Scholar
  58. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry. 2013;26:219–30.CrossRefGoogle Scholar
  59. Schulden JD, Thomas YF, Compton WM. Substance abuse in the United States: findings from recent epidemiologic studies. Curr Psychiatry Rep. 2009;11:353–9.CrossRefGoogle Scholar
  60. Scott J, Chant D, Andrews G. Psychotic-like experiences in the general community: the correlates of CIDI psychosis screen items in an Australian sample. Psychol Med. 2006;36:231–8.CrossRefGoogle Scholar
  61. Shain BN. Suicide and suicide attempts in adolescents. Pediatrics. 2007;120(3):669–76.CrossRefGoogle Scholar
  62. Singh MK, Ketter T, Chang KD. Distinguishing bipolar disorder from other psychiatric disorders in children. Curr Psychiatry Rep. 2014;16:516.  https://doi.org/10.1007/s11920-014-0516-2.CrossRefPubMedGoogle Scholar
  63. Stone AL, Becker LG, Huber AM, Catalano RF. Review of risk and protective factors of substance use and problem use in emerging adulthood. Addict Behav. 2012;37(7):747–75.CrossRefGoogle Scholar
  64. Strawn JR, Welge JA, Wehry AM, et al. Efficacy and tolerability of antidepressants in pediatrics anxiety disorders: a systematic review and meta-analysis. Depress Anxiety. 2015;32:149–57.CrossRefGoogle Scholar
  65. Swannell SV, Martin GE, Page A, Hasking P, St John NJ. Prevalence of nonsuicidal self-injury in nonclinical samples: systematic review, meta-analysis and meta-regression. Suicide Life Threat Behav. 2014;44:273–303.CrossRefGoogle Scholar
  66. Tang MH, Pinsky EG. Mood and affect disorders. Pediatr Rev. 2015;36(2):52–63.CrossRefGoogle Scholar
  67. Taylor E, Chadwick O, Heptinstall E, et al. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996;35:1213–26.CrossRefGoogle Scholar
  68. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240–50.CrossRefGoogle Scholar
  69. Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet. 2012;379(9820):1056–67.CrossRefGoogle Scholar
  70. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–86.CrossRefGoogle Scholar
  71. Thomsen PH. Schizophrenia with childhood and adolescent onset—a nationwide register-based study. Acta Psychiatr Scand. 1996;94:187–93.CrossRefGoogle Scholar
  72. Van Meter AR, Burke C, Youngstrum EA, et al. The bipolar prodrome: meta-analysis of symptom prevalence prior to initial or recurrent mood episodes. J Am Acad Child Adolesc Psychiatry. 2016;55(7):543–55.CrossRefGoogle Scholar
  73. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline or a combination in childhood anxiety. N Engl J Med. 2008;359:2753–66.CrossRefGoogle Scholar
  74. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132:132–49.CrossRefGoogle Scholar
  75. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009.Google Scholar
  76. Yung AR, Nelson B, Stanford C. Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105:10–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry, Dalhousie UniversityHalifaxCanada

Personalised recommendations